Preferred Label : Zimlovisertib;
NCIt definition : An orally bioavailable, small molecule, reversible inhibitor of interleukin-1 receptor-associated
kinase 4 (IRAK4), with potential immunomodulating and anti-inflammatory activities.
Upon oral administration, zimlovisertib targets, binds to, and blocks the kinase activity
of IRAK4. This inhibits IRAK4-mediated signaling, prevents the activation of IRAK4-mediated
nuclear factor-kappa B (NF-kB) signaling and decreases the expression of inflammatory
cytokines. This may inhibit inflammation and immune-mediated cell destruction in inflammatory
and auto-immune diseases where toll-like receptor (TLR) or interleukin 1 receptor
(IL-1R) signaling is overactivated and MYD88 is dysregulated. IRAK4, a serine/threonine-protein
kinase that plays a key role in both the TLR and IL-1R signaling pathways, is activated
though the adaptor protein MYD88 and links the TLR and IL-1R signaling pathway to
the NF-kB pathway.;
UNII : S3F315JJXI;
CAS number : 1817626-54-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1817626-54-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : PF 06650833; PF-06650833;
NCI Metathesaurus CUI : CL1773440;
Origin ID : C185226;
UMLS CUI : C5669777;
Semantic type(s)
- concept_is_in_subset
- has_target
